Cargando…
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
INTRODUCTION: The aim was to determine the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying cellular mechanisms. METHODS: PCI-32765 was ad...
Autores principales: | Chang, Betty Y, Huang, Min Mei, Francesco, Michelle, Chen, Jun, Sokolove, Jeremy, Magadala, Padmaja, Robinson, William H, Buggy, Joseph J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239353/ https://www.ncbi.nlm.nih.gov/pubmed/21752263 http://dx.doi.org/10.1186/ar3400 |
Ejemplares similares
-
Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021) -
Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021) -
Bruton’s Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis
por: Bonami, Rachel H., et al.
Publicado: (2022) -
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
por: Neys, Stefan F. H., et al.
Publicado: (2021) -
Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
por: Naik, Piyu Parth
Publicado: (2022)